'TransOG: a translational sub-study of OE02, OE05 and ST03
Research type
Research Study
Full title
'TransOG: a translational sub-study of OE02, OE05 and ST03
IRAS ID
257378
Contact name
David Cunningham
Contact email
Sponsor organisation
THE ROYAL MARSDEN NHS FOUNDATION
Clinicaltrials.gov Identifier
CCR 4584, TRANS OG OEO2, OEO5, AND STO3
Duration of Study in the UK
2 years, 5 months, 1 days
Research summary
The patient datasets from these three large clinical trials in early oesophagogastric cancer (OGC)(OE02, OE05 and ST03) of patients treated with surgery and chemotherapy represent an unparalleled opportunity to investigate possible markers which can predict which patients benefit most from chemotherapy and have better survival. Similarly, identifying which patients don't benefit from chemotherapy in this setting will spare them from significant and unnecessary side effects of this treatment.
In addition, a comprehensive analysis at the gene level of this large and well documented OGC clinical trial dataset could identify new treatment targets and gene changes which correlate with other characteristics of the patient or tumour. This should identify opportunities for personalized or tailored treatments for individual patients based on their underlying tumour characteristics and also provide important insights into the biology of these highly aggressive tumours.
REC name
South West - Cornwall & Plymouth Research Ethics Committee
REC reference
18/SW/0279
Date of REC Opinion
23 Dec 2018
REC opinion
Favourable Opinion